Author: kodiac

  • Xanomeline-Trospium

    Fixed-dose combination of an M1/M4-preferring muscarinic acetylcholine receptor agonist and a peripherally restricted non-selective muscarinic antagonist

    A first-in-class muscarinic agonist combination pairing the centrally acting M1/M4-preferring agonist xanomeline with the peripherally restricted muscarinic antagonist trospium chloride, approved by the United States Food and Drug Administration in September 2024 for the treatment of schizophrenia in adults, representing the first non-dopamine-D2-blocking antipsychotic mechanism registered for psychotic illness.

    Abstract

    Xanomeline-trospium (KarXT; marketed as Cobenfy) is a fixed-dose oral combination of xanomeline tartrate, a functionally selective muscarinic acetylcholine receptor agonist with preferential activity at the M1 and M4 receptor subtypes, and trospium chloride, a quaternary ammonium muscarinic antagonist that does not appreciably cross the blood-brain barrier. The combination was designed to preserve the central antipsychotic and procognitive effects of muscarinic M1/M4 agonism while mitigating the dose-limiting peripheral cholinergic adverse events (nausea, vomiting, diarrhea, hypersalivation, diaphoresis) that had previously terminated the clinical development of xanomeline as a monotherapy agent. The United States Food and Drug Administration approved xanomeline-trospium on 26 September 2024 for the treatment of schizophrenia in adults, making it the first antipsychotic mechanism approved since the introduction of the dopamine D2 receptor antagonist and partial agonist classes and the first muscarinic-based treatment registered for any psychotic disorder.

    Xanomeline was originally synthesized in a collaboration between Eli Lilly and Novo Nordisk in the early 1990s under the development code LY-246708. Initial clinical development targeted Alzheimer’s disease, where a 343-patient Phase 2 trial (Bodick et al. 1997) demonstrated stabilization of cognitive decline and significant dose-dependent reductions in behavioral and psychological symptoms including hallucinations, delusions, agitation, and vocal outbursts. However, peripheral cholinergic adverse events led to unacceptable dropout rates and the Alzheimer’s program was discontinued. A subsequent proof-of-concept trial in schizophrenia (Shekhar et al. 2008) confirmed antipsychotic-like activity through a non-dopaminergic mechanism but was similarly limited by tolerability. The critical innovation was the combination with trospium chloride, a muscarinic antagonist previously approved for overactive bladder (Sanctura, Allergan) that is restricted to the peripheral compartment by its quaternary ammonium structure and does not undergo cytochrome P450 metabolism. This combination strategy was advanced by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb for approximately 14 billion United States dollars in 2024.

    The registration of xanomeline-trospium was supported by three randomized, double-blind, placebo-controlled, 5-week Phase 3 trials (EMERGENT-1, EMERGENT-2, EMERGENT-3) in adults with schizophrenia experiencing acute psychosis. In pooled analyses across all three trials, xanomeline-trospium produced a statistically significant reduction in Positive and Negative Syndrome Scale (PANSS) total score compared to placebo (least squares mean difference, minus 9.9 points; 95 percent confidence interval, minus 12.4 to minus 7.3; p less than 0.0001; Cohen’s d effect size, 0.65). Effects were observed across positive symptom, negative symptom, and general psychopathology PANSS subscales and on the Clinical Global Impression-Severity scale. Long-term safety and efficacy were characterized in the 52-week open-label extension trials EMERGENT-4 and EMERGENT-5, which demonstrated sustained symptom improvement, a mean change in body weight of minus 1.9 kilograms from acute trial baseline, no clinically meaningful changes in prolactin levels, and no treatment-emergent akathisia or tardive dyskinesia. The most common adverse events were gastrointestinal (nausea, dyspepsia, constipation, vomiting) and were generally mild to moderate, transient, and manageable without treatment discontinuation in most patients.

    The compound is currently in Phase 3 development for additional indications including psychosis associated with Alzheimer’s disease (ADEPT program), agitation associated with Alzheimer’s disease (ADAGIO program), and cognitive impairment in Alzheimer’s disease. An enteric-coated xanomeline formulation (KarX-EC) is in development with the aim of further reducing gastrointestinal adverse events. This monograph reviews the chemistry, synthesis, and pharmacology of both components; the composite mechanism of action through central muscarinic M1/M4 agonism with peripheral muscarinic blockade; the pharmacokinetics including CYP2D6 polymorphism effects; the complete clinical evidence base across schizophrenia and Alzheimer’s disease indications; sourcing and quality considerations; reconstitution and handling; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five alternative antipsychotic or muscarinic-targeted agents against xanomeline-trospium on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1457Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Palmitoylethanolamide

    Plain-language summaryIntrigue 64 / 100

    Palmitoylethanolamide (PEA) is a fatty acid amide your body makes from membrane lipids, first identified in egg yolk in 1957 because of its anti-inflammatory effects. It does not bind cannabinoid receptors directly. Instead it activates the PPAR-alpha nuclear receptor, stabilizes mast cells (the immune cells that release histamine), and competes with anandamide for the FAAH enzyme, indirectly raising endocannabinoid tone. Decades of European clinical work, particularly in Italy, support its use for chronic pain, neuropathy, and sciatica, with a generally clean safety record and meaningful effect sizes. It is sold as a supplement in the US and as a registered medical food in parts of Europe. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Endogenous N-acylethanolamide lipid mediator with peroxisome proliferator-activated receptor alpha agonism and mast cell modulatory activity

    An endogenous fatty acid amide biosynthesized from membrane phospholipids, identified as an anti-inflammatory factor in the 1950s and subsequently characterized as a peroxisome proliferator-activated receptor alpha agonist with broad analgesic, anti-inflammatory, neuroprotective, and mast cell stabilizing activity across chronic pain, neuroinflammation, and neurodegenerative disease models.

    Abstract

    Palmitoylethanolamide (PEA; CAS 544-31-0; molecular formula C18H37NO2; molecular weight 299.49 g/mol) is an endogenous fatty acid amide of the N-acylethanolamide class, biosynthesized on demand from membrane N-palmitoyl-phosphatidylethanolamine by the enzyme N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) and degraded principally by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA) to palmitic acid and ethanolamine. The compound was first identified as a crystalline anti-inflammatory factor isolated from soybean lecithin by Kuehl et al. in 1957, following earlier observations by Coburn et al. (1954) that egg yolk protected against experimental anaphylactic arthritis. The Nobel laureate Rita Levi-Montalcini and colleagues subsequently characterized PEA as a modulator of mast cell degranulation and proposed the autacoid local injury antagonism (ALIA) mechanism in 1993, establishing the conceptual framework for PEA as an endogenous resolution factor in inflammation.

    The principal molecular target of PEA is the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha), at which PEA acts as a direct agonist with an EC50 of approximately 3.1 micromolar in cell-based reporter assays. Lo Verme et al. (2005) demonstrated that the anti-inflammatory actions of PEA in carrageenan-induced paw edema and phorbol ester-induced ear edema models are abolished in PPAR-alpha knockout mice, establishing PPAR-alpha as the principal mediator of PEA anti-inflammatory pharmacology. Additional receptor targets include the orphan G-protein coupled receptors GPR55 and GPR119, the transient receptor potential vanilloid type 1 channel (TRPV1, via indirect potentiation), and a mast cell surface receptor pharmacologically consistent with a peripheral cannabinoid site. PEA does not bind with meaningful affinity to classical cannabinoid receptors CB1 or CB2 but modulates the endocannabinoid system indirectly through an entourage mechanism: competition for FAAH-mediated degradation elevates tissue levels of the endocannabinoid anandamide, thereby potentiating anandamide signaling at CB1, CB2, and TRPV1.

    The clinical evidence base for PEA spans chronic pain, neuropathic pain, neuroinflammation, and neurodegenerative disease. A 2023 systematic review and meta-analysis of double-blind randomized controlled trials (Scuteri et al., Nutrients, 2023) encompassing 12 studies and approximately 1300 patients demonstrated that oral PEA at 300 to 1200 mg daily produces statistically significant and clinically meaningful pain intensity reduction compared to placebo or active control, with effect emerging at 30 days and increasing through 60 days of treatment. Specific indications with positive randomized controlled trial evidence include sciatic pain, diabetic peripheral neuropathy, carpal tunnel syndrome, temporomandibular joint disorder, chronic low back pain, endometriosis-associated pelvic pain, and fibromyalgia. Micronized (mPEA) and ultramicronized (umPEA) particle-size formulations have been developed to overcome the poor aqueous solubility and limited oral bioavailability of native crystalline PEA, with the micronization process increasing the specific surface area and producing substantially improved absorption and tissue distribution.

    PEA exhibits a favorable safety profile consistent with its status as an endogenous compound and a natural component of the human diet (present in egg yolk, soybean lecithin, peanut meal, and other food sources). Across more than 40 clinical studies and approximately 3000 patient-exposures, no serious adverse drug reactions have been attributed to PEA supplementation at doses up to 1200 mg daily for up to 120 days. The compound is marketed as a medical food or dietary supplement in multiple European jurisdictions (Normast, PeaPure, Levagen) and is available as a research-grade preparation from multiple chemical suppliers. PEA is not approved as a drug by the United States Food and Drug Administration or by the European Medicines Agency; its regulatory status varies by jurisdiction between dietary supplement, medical food, and food for special medical purposes.

    This monograph documents the chemistry, biosynthesis, and degradation of PEA; the multi-target molecular pharmacology including PPAR-alpha agonism, GPR55 and GPR119 signaling, mast cell modulation, and entourage potentiation of endocannabinoid tone; the pharmacokinetic profile with emphasis on formulation-dependent bioavailability; the preclinical pharmacology across pain, inflammation, and neurodegeneration models; the clinical evidence base in chronic and neuropathic pain, neuroinflammatory conditions, and neurodegenerative disease; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative anti-inflammatory lipid mediators (cannabidiol, oleoylethanolamide, stearoylethanolamide, N-arachidonoylethanolamide, and resolvin E1) against PEA on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1494Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • BAM15

    Mitochondria-selective protonophore uncoupler of oxidative phosphorylation

    A synthetic oxadiazolopyrazine-scaffold mitochondrial protonophore distinguished from classical uncouplers by selective dissipation of the inner mitochondrial membrane proton gradient without depolarization of the plasma membrane, conferring potent metabolic enhancement with markedly reduced cytotoxicity in preclinical models of obesity, insulin resistance, hepatic steatosis, sepsis, and cancer.

    Abstract

    BAM15 (N5,N6-bis(2-fluorophenyl)-[1,2,5]oxadiazolo[3,4-b]pyrazine-5,6-diamine) is a synthetic small-molecule mitochondrial protonophore first identified in a 2014 phenotypic screen by Kenwood et al. at the University of Virginia and Virginia Tech for compounds that uncouple mitochondrial oxidative phosphorylation without depolarizing the plasma membrane [1]. The compound dissipates the electrochemical proton gradient across the inner mitochondrial membrane, thereby uncoupling electron transport from adenosine triphosphate (ATP) synthesis and increasing substrate oxidation and energy expenditure. Unlike the classical protonophore uncouplers 2,4-dinitrophenol (DNP) and carbonylcyanide-p-trifluoromethoxyphenylhydrazone (FCCP), BAM15 selectively targets the mitochondrial membrane and does not collapse the plasma membrane potential at effective uncoupling concentrations, a property that confers a substantially wider therapeutic index and reduced cytotoxicity in cultured cells and in vivo [1, 2]. The compound is orally bioavailable in mice (67 percent oral bioavailability, Cmax 8.2 micromolar, t1/2 1.7 hours) with primary distribution to the liver, supporting hepatic metabolic applications [3]. In C57BL/6J mice fed a high-fat diet, BAM15 administered at 100 mg/kg/day by oral gavage reversed diet-induced obesity, decreased body fat mass without altering food intake or lean body mass, reduced hepatic triglycerides by approximately 75 percent, decreased inflammatory lipids, and improved whole-body insulin sensitivity as demonstrated by hyperinsulinemic-euglycemic clamp [3]. In a head-to-head comparison in female db/db mice, BAM15 and calorie restriction improved body weight and liver steatosis to levels superior to semaglutide, niclosamide ethanolamine (NEN), and rosiglitazone, while BAM15, semaglutide, and rosiglitazone completely restored glucose tolerance [4]. These metabolic effects are mediated through sustained activation of AMP-activated protein kinase (AMPK) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1alpha), promoting fatty acid oxidation, glucose uptake, and mitochondrial biogenesis [2, 5]. Beyond metabolic disease, BAM15 has demonstrated preclinical efficacy in acute kidney injury and sepsis (reducing mortality even when administered 12 hours after cecal ligation and puncture in mice) [6], in acute myeloid leukemia (inhibiting AML cell proliferation and inducing reactive oxygen species-mediated apoptosis with selectivity over normal cells) [7], in sarcopenic obesity (preserving skeletal muscle contractility and mitochondrial respiration in aged mice) [8, 9], in atherosclerosis (suppressing western diet-induced plaque formation in ApoE-knockout mice through AMPK activation and NF-kappaB/NLRP3 inflammasome suppression) [10, 11], and in vascular smooth muscle relaxation [5]. Safety pharmacology in rodents has demonstrated no alteration of body temperature, food intake, lean body mass, or standard hematological and biochemical markers of toxicity at effective metabolic doses [3]. BAM15 has not entered human clinical trials as of the most recent monograph revision. The compound is supplied as a research-grade material by multiple chemical suppliers at greater than 98 percent purity and is not approved by any regulatory authority for therapeutic use. This monograph documents the chemistry, synthesis, discovery history, molecular pharmacology, pharmacokinetics, preclinical evidence base across metabolic, inflammatory, oncologic, and aging indications, sourcing and quality verification, reconstitution and handling, stack-interaction considerations, adverse-event profile, and a structured comparative assessment against five alternative mitochondrial uncouplers.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1470Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Palmitoylethanolamide (PEA)

    Endogenous N-acylethanolamide lipid mediator with peroxisome proliferator-activated receptor alpha agonism and mast cell modulatory activity

    An endogenous fatty acid amide biosynthesized from membrane phospholipids, identified as an anti-inflammatory factor in the 1950s and subsequently characterized as a peroxisome proliferator-activated receptor alpha agonist with broad analgesic, anti-inflammatory, neuroprotective, and mast cell stabilizing activity across chronic pain, neuroinflammation, and neurodegenerative disease models.

    Abstract

    Palmitoylethanolamide (PEA; CAS 544-31-0; molecular formula C18H37NO2; molecular weight 299.49 g/mol) is an endogenous fatty acid amide of the N-acylethanolamide class, biosynthesized on demand from membrane N-palmitoyl-phosphatidylethanolamine by the enzyme N-acyl-phosphatidylethanolamine-selective phospholipase D (NAPE-PLD) and degraded principally by fatty acid amide hydrolase (FAAH) and N-acylethanolamine-hydrolyzing acid amidase (NAAA) to palmitic acid and ethanolamine. The compound was first identified as a crystalline anti-inflammatory factor isolated from soybean lecithin by Kuehl et al. in 1957, following earlier observations by Coburn et al. (1954) that egg yolk protected against experimental anaphylactic arthritis. The Nobel laureate Rita Levi-Montalcini and colleagues subsequently characterized PEA as a modulator of mast cell degranulation and proposed the autacoid local injury antagonism (ALIA) mechanism in 1993, establishing the conceptual framework for PEA as an endogenous resolution factor in inflammation.

    The principal molecular target of PEA is the nuclear receptor peroxisome proliferator-activated receptor alpha (PPAR-alpha), at which PEA acts as a direct agonist with an EC50 of approximately 3.1 micromolar in cell-based reporter assays. Lo Verme et al. (2005) demonstrated that the anti-inflammatory actions of PEA in carrageenan-induced paw edema and phorbol ester-induced ear edema models are abolished in PPAR-alpha knockout mice, establishing PPAR-alpha as the principal mediator of PEA anti-inflammatory pharmacology. Additional receptor targets include the orphan G-protein coupled receptors GPR55 and GPR119, the transient receptor potential vanilloid type 1 channel (TRPV1, via indirect potentiation), and a mast cell surface receptor pharmacologically consistent with a peripheral cannabinoid site. PEA does not bind with meaningful affinity to classical cannabinoid receptors CB1 or CB2 but modulates the endocannabinoid system indirectly through an entourage mechanism: competition for FAAH-mediated degradation elevates tissue levels of the endocannabinoid anandamide, thereby potentiating anandamide signaling at CB1, CB2, and TRPV1.

    The clinical evidence base for PEA spans chronic pain, neuropathic pain, neuroinflammation, and neurodegenerative disease. A 2023 systematic review and meta-analysis of double-blind randomized controlled trials (Scuteri et al., Nutrients, 2023) encompassing 12 studies and approximately 1300 patients demonstrated that oral PEA at 300 to 1200 mg daily produces statistically significant and clinically meaningful pain intensity reduction compared to placebo or active control, with effect emerging at 30 days and increasing through 60 days of treatment. Specific indications with positive randomized controlled trial evidence include sciatic pain, diabetic peripheral neuropathy, carpal tunnel syndrome, temporomandibular joint disorder, chronic low back pain, endometriosis-associated pelvic pain, and fibromyalgia. Micronized (mPEA) and ultramicronized (umPEA) particle-size formulations have been developed to overcome the poor aqueous solubility and limited oral bioavailability of native crystalline PEA, with the micronization process increasing the specific surface area and producing substantially improved absorption and tissue distribution.

    PEA exhibits a favorable safety profile consistent with its status as an endogenous compound and a natural component of the human diet (present in egg yolk, soybean lecithin, peanut meal, and other food sources). Across more than 40 clinical studies and approximately 3000 patient-exposures, no serious adverse drug reactions have been attributed to PEA supplementation at doses up to 1200 mg daily for up to 120 days. The compound is marketed as a medical food or dietary supplement in multiple European jurisdictions (Normast, PeaPure, Levagen) and is available as a research-grade preparation from multiple chemical suppliers. PEA is not approved as a drug by the United States Food and Drug Administration or by the European Medicines Agency; its regulatory status varies by jurisdiction between dietary supplement, medical food, and food for special medical purposes.

    This monograph documents the chemistry, biosynthesis, and degradation of PEA; the multi-target molecular pharmacology including PPAR-alpha agonism, GPR55 and GPR119 signaling, mast cell modulation, and entourage potentiation of endocannabinoid tone; the pharmacokinetic profile with emphasis on formulation-dependent bioavailability; the preclinical pharmacology across pain, inflammation, and neurodegeneration models; the clinical evidence base in chronic and neuropathic pain, neuroinflammatory conditions, and neurodegenerative disease; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five alternative anti-inflammatory lipid mediators (cannabidiol, oleoylethanolamide, stearoylethanolamide, N-arachidonoylethanolamide, and resolvin E1) against PEA on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1494Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • CDD-0102

    Selective M1 muscarinic acetylcholine receptor partial agonist of the tetrahydropyrimidine-oxadiazole structural class

    A functionally selective partial agonist at the M1 muscarinic acetylcholine receptor developed at the University of Toledo as a cognitive enhancer and neuroprotective agent for Alzheimer’s disease, distinguished from earlier muscarinic agonists by subtype selectivity, low cholinergic adverse-event burden, and oral bioavailability.

    Abstract

    CDD-0102, the hydrochloride salt of 5-(3-ethyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidine (designated CDD-0102A in its salt form), is a functionally selective partial agonist at the M1 subtype of the muscarinic acetylcholine receptor developed at the University of Toledo College of Pharmacy under the direction of W.S. Messer Jr. as a candidate therapeutic for Alzheimer’s disease and related cognitive disorders. The compound occupies the orthosteric acetylcholine-binding site of the M1 receptor with partial agonist intrinsic activity sufficient to activate phospholipase C-coupled signaling, stimulate non-amyloidogenic processing of amyloid precursor protein (APP) through alpha-secretase, and enhance cognitive function in rodent models of cholinergic deficit, while exhibiting minimal functional activity at M2, M4, and M5 muscarinic subtypes and only weak activity at M3 receptors. This functional selectivity profile distinguishes CDD-0102 from the first-generation M1-preferring muscarinic agonists (xanomeline, sabcomeline, talsaclidine, cevimeline) that produced dose-limiting cholinergic adverse events (salivation, gastrointestinal disturbance, diaphoresis) attributable to activation of peripheral M2 and M3 receptors, a limitation that terminated or constrained the clinical development of each of those compounds in the Alzheimer’s indication. The pharmacological characterization of CDD-0102 encompasses M1-selective receptor binding, stimulation of soluble APP-alpha (sAPPalpha) secretion from Chinese hamster ovary cells stably expressing human M1 receptors, neuroprotective activity in cell culture, brain penetration following systemic administration in rodents, oral bioavailability, and a favorable acute toxicity profile. In behavioral pharmacology, CDD-0102A administered intraperitoneally at doses of 0.03 to 1.0 mg/kg enhances delayed spontaneous alternation in a four-arm cross maze (a measure of spatial working memory) and facilitates strategy switching between place and visual-cue discriminations (a measure of cognitive flexibility), with both effects following a dose-dependent profile and occurring at doses below the threshold for salivation (approximately 0.3 mg/kg intraperitoneal for the minimum effective salivation dose, with an estimated ED50 for salivation of 2.0 mg/kg). More recent preclinical work has extended the pharmacological profile to autism spectrum disorder models, demonstrating that CDD-0102A attenuates stereotyped motor behaviors (self-grooming, digging) and modulates glutamate efflux in dorsolateral striatum of the BTBR T+ Itpr3tf/J mouse, a model of autism-relevant repetitive behavior and social deficit. The compound advanced through preclinical development with support from the National Center for Advancing Translational Sciences (NCATS) Bridging Interventional Development Gaps (BrIDGs) program, which funded the IND-enabling studies including synthetic scale-up, formulation, pharmacokinetics, and toxicology. An Investigational New Drug (IND) application was filed with the United States Food and Drug Administration, and Phase 1 clinical testing was initiated. Published results from Phase 1 clinical evaluation have not appeared in the peer-reviewed literature as of the most recent monograph revision. The compound is not registered as a marketed medicine in any jurisdiction. This monograph reviews the chemistry, synthesis, and structural class of CDD-0102; the M1 muscarinic receptor pharmacology in molecular and functional detail; the preclinical evidence base across Alzheimer’s disease, cognitive flexibility, and autism-relevant endpoints; the available pharmacokinetic characterization; sourcing and quality verification considerations for research applications; reconstitution and handling; stack-interaction considerations; the adverse-event and safety profile; and a comparative assessment of five M1 muscarinic receptor agonist candidates (xanomeline, sabcomeline, talsaclidine, AF267B, cevimeline) against CDD-0102 on five competency standards (novelty, effect size, promising potential, side-effect profile, and overall validation).

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1458Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Noopept

    Plain-language summaryIntrigue 70 / 100

    Noopept is a Russian-developed dipeptide nootropic that gets metabolized to cycloprolylglycine in the body. It supports BDNF and NGF expression and has memory-enhancing effects in animal studies at very low doses. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Synthetic dipeptide nootropic and neuroprotectant derived from cycloprolylglycine with AMPA receptor positive allosteric modulation and neurotrophic factor upregulation

    A proline-glycine dipeptide cognitive enhancer (GVS-111) developed at the Zakusov Institute of Pharmacology in Russia, distinguished from classical racetam nootropics by approximately 1000-fold greater mass potency, rapid conversion to the endogenous neuropeptide cycloprolylglycine, and a multifactorial mechanism encompassing AMPA receptor positive allosteric modulation, NMDA receptor modulation, NGF and BDNF upregulation, HIF-1 transcription factor activation, and neuroprotection against amyloid-beta toxicity and tau hyperphosphorylation.

    Abstract

    Noopept (INN: omberacetam; development code GVS-111; N-phenylacetyl-L-prolylglycine ethyl ester; CAS 157115-85-0; molecular formula C17H22N2O4; molecular weight 318.37 g/mol) is a synthetic dipeptide nootropic and neuroprotectant developed in the mid-1990s at the V.V. Zakusov Research Institute of Pharmacology of the Russian Academy of Medical Sciences by Tatyana Gudasheva, Rita Ostrovskaya, and Sergei Seredenin using a drug-based peptide design strategy that models the pyrrolidone ring of piracetam as the central element of a beta-turn dipeptide. The compound is approved in the Russian Federation (registration 2006) and several former Soviet states for the treatment of cognitive impairment of vascular and post-traumatic origin at oral doses of 10 to 30 mg per day, doses approximately 1000-fold lower by mass than the effective doses of piracetam (1200 to 4800 mg per day), its structural prototype. Noopept is not approved by the United States Food and Drug Administration, the European Medicines Agency, or the regulatory authorities of Japan, Australia, or Canada. It is sold internationally as a research-grade compound and as an unregulated dietary supplement in several jurisdictions.

    The pharmacological mechanism of noopept is multifactorial and operates through both the parent compound and its principal active metabolite, cycloprolylglycine (cyclo-L-prolylglycine, CPG), an endogenous brain dipeptide. The parent compound and CPG function as positive allosteric modulators of AMPA-subtype ionotropic glutamate receptors, increasing glutamate sensitivity without direct agonist binding. Noopept modulates NMDA receptor expression and function, upregulates the expression of nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF) in hippocampal and cortical neurons on chronic administration, activates the transcription factor hypoxia-inducible factor 1 (HIF-1) through inhibition of prolyl hydroxylase, and provides direct neuroprotection against amyloid-beta peptide toxicity, glutamate excitotoxicity, oxidative stress, and calcium overload in cellular and animal models. In Alzheimer’s disease cellular models, noopept attenuates tau hyperphosphorylation at Ser396 and reduces apoptosis through suppression of the mitochondrial apoptotic pathway.

    Pharmacokinetics in humans are characterized by rapid oral absorption (time to peak plasma concentration approximately 15 to 20 minutes), extensive first-pass metabolism yielding an oral bioavailability of approximately 10 percent relative to parenteral administration, rapid hydrolysis of the parent ester to the active metabolite cycloprolylglycine, and a short plasma half-life of the parent compound. The pharmacological effect persists for 3 to 6 hours after oral dosing, substantially longer than the plasma residence of the parent compound, consistent with the contribution of the longer-lived CPG metabolite and downstream transcriptional effects on neurotrophic factor expression. The compound does not appear to undergo significant cytochrome P450-mediated metabolism; the principal biotransformation is peptidase-mediated ester hydrolysis and amide cleavage.

    The clinical evidence base is concentrated in Russian-language literature and is modest by Western regulatory standards. The principal English-language clinical study is the Neznamov and Teleshova (2009) comparative trial of noopept (20 mg per day) and piracetam (1200 mg per day) in 53 patients with mild cognitive disorders of vascular and traumatic origin over 56 days, which demonstrated comparable cognitive improvement with a 1.8-fold lower incidence of adverse events in the noopept arm. Preclinical evidence is more extensive, spanning rodent models of ischemic brain injury, Alzheimer’s disease (both amyloid-beta infusion and transgenic models), traumatic brain injury, and age-related cognitive decline. The compound is well tolerated at recommended doses; the principal adverse events are sleep disturbance, irritability, and transient blood pressure elevation, all at low incidence. No serious adverse events have been reported in published clinical studies at doses up to 30 mg per day for periods up to 56 days. Long-term safety data beyond 56 days of continuous administration are not available.

    This monograph reviews the chemistry, synthesis, and structural pharmacology of noopept; the multifactorial mechanism of action including AMPA receptor modulation, NMDA receptor effects, neurotrophic factor upregulation, HIF-1 activation, and amyloid-beta neuroprotection; the pharmacokinetic profile with emphasis on the cycloprolylglycine metabolite; the preclinical pharmacology across ischemic, neurodegenerative, and traumatic models; the clinical evidence base; sourcing and quality verification; reconstitution and handling; stack interactions and combinations; adverse events and safety signal; and a comparative assessment of five nootropic alternatives (piracetam, aniracetam, phenylpiracetam, semax, and cerebrolysin) against noopept on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1430Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Phenylpiracetam (Phenotropil)

    Plain-language summaryIntrigue 60 / 100

    Phenylpiracetam (Phenotropil) is a phenylated piracetam analog developed in Russia. It produces stimulating cognitive effects and is reported to have antidepressant properties. Banned by WADA in sport. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Racetam-class nootropic and psychostimulant with dopamine transporter inhibition, nicotinic acetylcholine receptor modulation, and AMPA receptor positive allosteric modulation

    A 4-phenyl derivative of piracetam developed at the Russian Institute of Biomedical Problems as a cosmonaut performance enhancer, distinguished from the parent racetam by stereoselective dopamine transporter inhibition, enhanced blood-brain barrier penetration, psychostimulant activity, and a broader pharmacological profile spanning cognition, neuroprotection, cold tolerance, and anti-inflammatory effects.

    Abstract

    Phenylpiracetam (fonturacetam, INN; carphedon; 4-phenylpiracetam) is a racetam-class nootropic and psychostimulant first described by Bobkov et al. in 1983 and developed at the Institute of Biomedical Problems of the Russian Academy of Sciences for the enhancement of cognitive, physical, and thermoregulatory performance in cosmonauts operating under conditions of sustained stress, microgravity, and cold exposure. The compound is the 4-phenyl-substituted analog of piracetam and was approved for medical use in Russia in 2003 under the trade name Phenotropil for indications including cerebrovascular insufficiency, cognitive decline following stroke or traumatic brain injury, depression, asthenia, and attentional disorders. Phenylpiracetam is approximately 20- to 60-fold more potent than piracetam in animal models of cognition and anticonvulsant activity, an enhancement attributed to the phenyl substituent conferring increased lipophilicity, improved blood-brain barrier penetration, and direct engagement with monoaminergic and glutamatergic receptor systems that the parent compound does not meaningfully occupy. The molecular pharmacology of phenylpiracetam has been substantially clarified by the work of Zvejniece, Dambrova, and colleagues at the Latvian Institute of Organic Synthesis, who demonstrated in 2011 that the racemic compound binds the alpha-4-beta-2 subtype of the nicotinic acetylcholine receptor with an IC50 of 5.86 micromolar, and in 2017 that the individual enantiomers exhibit divergent dopamine transporter (DAT) pharmacology: (R)-phenylpiracetam is a dual norepinephrine-dopamine reuptake inhibitor with an IC50 at DAT of approximately 14.5 micromolar and 11-fold lower affinity for the norepinephrine transporter, while (S)-phenylpiracetam is a selective DAT inhibitor that reduces body weight gain in obese Zucker rats and diet-induced obesity models without producing the locomotor stimulation characteristic of the (R)-enantiomer [1, 2]. The (R)-enantiomer is the more pharmacologically active form for psychostimulant and procognitive effects and is the subject of independent patent filings for Parkinson disease, sleep disorders, and disease-associated fatigue. Both enantiomers additionally modulate AMPA-type glutamate receptors through positive allosteric modulation, consistent with the broader racetam class mechanism, and contribute to neuroprotective and anti-inflammatory activity demonstrated in lipopolysaccharide and carrageenan inflammation models [3]. Pharmacokinetics in humans are characterized by rapid oral absorption with near-complete bioavailability, a time to maximum plasma concentration of approximately one hour, a plasma elimination half-life of three to five hours, and negligible hepatic metabolism: the compound is excreted essentially unchanged, with approximately 40 percent recovered in urine and 60 percent in bile and sweat. The absence of cytochrome P450 involvement eliminates the polymorphic pharmacokinetic variability that complicates other nootropic and psychostimulant agents and reduces drug-drug interaction liability. Clinical evidence is derived predominantly from Russian-language trials of moderate methodological rigor. A 12-month study in approximately 400 post-stroke patients demonstrated enhanced recovery of neurological function and cognitive performance relative to standard rehabilitation. A 30-day trial in 99 patients with cognitive deficits secondary to surgery or traumatic brain injury reported significant improvements in motor coordination, memory, attention, and higher brain function at 200 mg daily. An adjunctive epilepsy trial reported seizure frequency reduction and cognitive benefit. The compound has been on the World Anti-Doping Agency Prohibited List since 1998 as a stimulant (class S6), following detection in athlete doping control samples at the 1997 World Athletics Championships. This monograph reviews the chemistry, synthesis, and stereochemistry of phenylpiracetam; the dopaminergic, nicotinic, and glutamatergic receptor pharmacology with enantiomer-resolved detail; human pharmacokinetics; the preclinical and clinical evidence base across cognitive, neuroprotective, anti-inflammatory, metabolic, and physical performance domains; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse-event and safety signal; and a comparative assessment of five alternative nootropic and procognitive compounds against phenylpiracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1428Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Oxiracetam

    Plain-language summaryIntrigue 55 / 100

    Oxiracetam is a hydroxylated piracetam analog with reportedly stimulating cognitive effects. It is widely used in Italy and other European countries for cognitive impairment. Effects include enhanced memory consolidation in animal studies. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    2-Pyrrolidinone nootropic of the racetam family with positive allosteric modulation of AMPA-type glutamate receptors and protein kinase C activation

    A hydroxylated cyclic derivative of gamma-aminobutyric acid developed by ISF in Italy as a second-generation racetam nootropic, distinguished from piracetam by enhanced potency, positive allosteric modulation of AMPA receptors, stimulation of membrane-bound protein kinase C, and augmentation of hippocampal glutamate and acetylcholine release.

    Abstract

    Oxiracetam (ISF 2522, CGP 21690E) is a synthetic nootropic of the 2-pyrrolidinone (racetam) class, first synthesized in 1974 at the Istituto di Ricerche Farmacologiche (ISF) in Milan and introduced to the Italian market in 1984 under the trade name Neuromet for the treatment of cognitive disorders associated with primary degenerative dementia and multi-infarct dementia of mild to moderate degree. The compound is the 4-hydroxy analog of piracetam, the parent racetam; the hydroxyl substitution at position 4 of the pyrrolidinone ring produces a chiral center and confers approximately 2- to 5-fold greater potency than piracetam in standard rodent learning and memory paradigms and in in vitro assays of neurotransmitter release and synaptic potentiation. Oxiracetam is supplied and marketed as the racemic mixture of (R)- and (S)-enantiomers, though recent research has identified (S)-oxiracetam as the pharmacologically active enantiomer responsible for cognitive improvement in chronic cerebral hypoperfusion models.

    The mechanism of action of oxiracetam is multimodal and incompletely characterized at the molecular level, consistent with the broader racetam class. The principal identified activities include positive allosteric modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, producing enhanced glutamatergic neurotransmission and facilitation of long-term potentiation in hippocampal circuits; stimulation of membrane-bound protein kinase C (PKC), particularly the alpha and gamma isoforms, with consequent phosphorylation of substrates involved in memory consolidation and synaptic plasticity; augmentation of hippocampal acetylcholine release through modulation of cholinergic interneuron excitability; and stimulation of phospholipid metabolism in neuronal membranes. Oxiracetam also increases the release of endogenous glutamate and D-aspartic acid from depolarized hippocampal slices, supporting a presynaptic facilitatory component of its mechanism. A 2020 study further demonstrated that oxiracetam attenuates amyloid-beta-induced microglial activation and reduces neuroinflammatory cytokine release (interleukin-1-beta, interleukin-6, and tumor necrosis factor alpha), adding an anti-inflammatory dimension to the pharmacological profile.

    Pharmacokinetics in humans are characterized by oral bioavailability of 56 to 82 percent, peak plasma concentrations within 1 to 3 hours of dosing, and an elimination half-life of approximately 8 hours in healthy subjects. The compound is not appreciably metabolized; approximately 84 percent of an administered oral dose is recovered unchanged in urine within 24 hours, reflecting predominantly renal clearance. Brain penetration is modest, with central nervous system concentrations reaching approximately 5.3 percent of simultaneous blood levels. In patients with renal impairment, the elimination half-life extends to 10 to 68 hours, necessitating dose adjustment. The compound does not bind significantly to plasma proteins and does not undergo hepatic cytochrome P450 metabolism, resulting in a low drug-drug interaction potential.

    The clinical evidence base spans multiple indications. In mild to moderate dementia of the Alzheimer type and multi-infarct dementia, multicenter randomized placebo-controlled trials conducted in Italy in the late 1980s and early 1990s demonstrated statistically significant improvements in cognitive function at 800 mg twice daily for 12 to 52 weeks, measured by the Mini Mental State Examination, memory batteries, and functional scales. A negative trial in Alzheimer’s disease (Green et al., 1992) and mixed results in traumatic brain injury temper the clinical profile. More recently, a 2025 multicenter phase 3 trial of the purified (S)-enantiomer (L-oxiracetam) in 590 patients with mild to moderate traumatic brain injury reported significantly greater cognitive improvement than both racemic oxiracetam and placebo at 90 days. A 2023 phase IV trial of racemic oxiracetam in post-stroke vascular cognitive impairment in South Korea did not support efficacy in preventing cognitive decline. The compound is approved as a prescription medicine in Italy, select European countries, Argentina, and China; it is not approved by the United States Food and Drug Administration.

    This monograph reviews the chemistry, stereochemistry, and synthesis of oxiracetam; the multimodal molecular pharmacology including AMPA receptor modulation, PKC activation, neurotransmitter release augmentation, and anti-inflammatory activity; the comprehensive human pharmacokinetic record; the clinical evidence base across dementia, vascular cognitive impairment, traumatic brain injury, and neuroprotection indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions; adverse-event signal; and a comparative assessment of five nootropic alternatives against oxiracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1427Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Pramiracetam

    Plain-language summaryIntrigue 55 / 100

    Pramiracetam is a more potent piracetam analog with strong effects on hippocampal acetylcholine release. It is used in Italy for neurological disorders and is popular in nootropic communities for memory enhancement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Diisopropylaminoethyl 2-oxopyrrolidineacetamide racetam nootropic with selective high-affinity choline uptake potentiation

    A lipophilic piracetam analog developed at Parke-Davis as a cognition-enhancing agent, distinguished from the parent racetam by potent modulation of hippocampal high-affinity choline uptake and marketed in select European jurisdictions for age-related cognitive impairment and attention deficits.

    Abstract

    Pramiracetam (CI-879; N-[2-(diisopropylamino)ethyl]-2-(2-oxopyrrolidin-1-yl)acetamide; CAS 68497-62-1; molecular formula C14H27N3O2; molecular weight 269.39 g/mol) is a second-generation nootropic of the racetam class, synthesized at Parke-Davis in the late 1970s as a structural analog of piracetam. The compound differs from piracetam by replacement of the primary amide group with a diisopropylaminoethyl amide, a modification that substantially increases lipophilicity, central nervous system penetration, and effective potency, permitting therapeutic doses approximately five to ten times lower than equivalent piracetam regimens. Pramiracetam was advanced through preclinical and clinical development at Parke-Davis (then a division of Warner-Lambert, subsequently acquired by Pfizer) with the development code CI-879. The compound was licensed to Menarini for European development and was marketed under the trade names Pramistar, Neupramir, and Remen in Italy, Belgium, and several Eastern European jurisdictions for the treatment of memory and attention deficits in aging populations with neurodegenerative and vascular dementias. The Italian marketing authorization under Menarini was maintained until 2020, when it was voluntarily withdrawn by the manufacturer. The principal pharmacological mechanism of pramiracetam, characterized in the Pugsley et al. (1983) and subsequent studies, is selective enhancement of high-affinity choline uptake (HACU) in hippocampal and cortical cholinergic nerve terminals [1]. HACU is the rate-limiting step in acetylcholine biosynthesis; pramiracetam increases the velocity of choline transport into presynaptic cholinergic neurons without altering monoamine neurotransmitter concentrations, receptor binding profiles at dopaminergic, serotonergic, adrenergic, or histaminergic sites, or monoamine oxidase activity. The selectivity of the HACU mechanism distinguishes pramiracetam from piracetam, which acts predominantly through AMPA receptor positive allosteric modulation and membrane fluidity enhancement. Additional preclinical findings include increased nitric oxide synthase activity in rat cerebral cortex following systemic administration [2] and normalization of age-related electroencephalographic abnormalities in aged Fischer-344 rats [3]. The compound does not exhibit direct cholinesterase inhibition, muscarinic or nicotinic receptor agonism, or GABAergic activity at pharmacologically relevant concentrations. Pharmacokinetics in healthy human volunteers are characterized by rapid oral absorption, with peak plasma concentrations attained in approximately two to three hours; a plasma elimination half-life of 4.5 to 6.5 hours; linear dose-proportional exposure across the studied dose range (400 to 1600 mg); negligible plasma protein binding; and predominantly renal excretion of unchanged drug with minimal hepatic metabolism [4, 5]. The absence of significant cytochrome P450 involvement reduces drug-drug interaction liability relative to hepatically metabolized nootropic and cholinergic agents. The clinical evidence base includes a two-phase placebo-controlled trial in probable Alzheimer disease conducted at the National Institutes of Neurological Disorders and Stroke (Claus et al., 1991), which found that doses up to 4000 mg daily were unlikely to confer symptomatic benefit in moderate-to-severe Alzheimer disease [6]; a placebo-controlled study of scopolamine-induced amnesia in healthy volunteers demonstrating partial reversal of anticholinergic memory impairment in both young and elderly subjects [7]; a small open-label study in traumatic brain injury rehabilitation showing improved cognitive recovery [8]; and the European registration trials conducted by Menarini supporting the indication for memory and attention deficits in elderly patients with neurodegenerative and vascular dementias. Effect sizes across these studies are consistently small to moderate, and the compound has not produced a positive Phase 3 registration-quality readout in Alzheimer disease. Pramiracetam is not approved by the United States Food and Drug Administration and is classified as an unapproved new drug in the United States. It is available as a research-grade chemical from multiple suppliers. This monograph documents the chemistry, synthesis, and structural pharmacology of pramiracetam; the high-affinity choline uptake mechanism and supporting preclinical pharmacology; the comprehensive human pharmacokinetic record; the clinical evidence base across cognitive indications; sourcing and quality verification considerations; reconstitution and handling; stack-interaction implications for research use; adverse-event signal; and a structured comparative assessment of five racetam-class and cholinergic nootropic compounds against pramiracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1429Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

  • Aniracetam

    Plain-language summaryIntrigue 62 / 100

    Aniracetam is a more potent racetam approved in Europe and Asia. It modulates AMPA glutamate receptors, slowing receptor desensitization, and is reported to have anxiolytic effects beyond cognition. Fat-soluble (best absorbed with food). Not stocked by Kodiac. This monograph is provided for research and educational reference.

    Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

    Pyrrolidinone-class positive allosteric modulator of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors with secondary cholinergic, dopaminergic, and serotonergic neuromodulatory activity

    A lipophilic racetam nootropic developed at Hoffmann-La Roche as a cognition enhancer for cerebrovascular and neurodegenerative disorders, distinguished from piracetam by higher potency, oral lipophilicity, AMPA receptor positive allosteric modulation, and multi-target downstream activation of cholinergic, dopaminergic, and serotonergic neurotransmission through pharmacologically active metabolites.

    Abstract

    Aniracetam (1-(4-methoxybenzoyl)-2-pyrrolidinone; Ro 13-5057) is a lipophilic pyrrolidinone derivative of the racetam structural class, originally synthesized at Hoffmann-La Roche in the late 1970s as a more potent and centrally bioavailable analog of piracetam for the treatment of cognitive dysfunction associated with cerebrovascular disease and neurodegenerative dementia. The compound is classified as a positive allosteric modulator (PAM) of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) subtype of ionotropic glutamate receptor, a mechanism that slows both channel deactivation and receptor desensitization at synaptic AMPA receptors, thereby prolonging excitatory postsynaptic currents and enhancing glutamatergic neurotransmission in cortical and hippocampal circuits critical for learning and memory [1, 2]. Beyond the direct AMPA receptor modulation, aniracetam and its principal active metabolite N-anisoyl-gamma-aminobutyric acid (N-anisoyl-GABA, which accounts for 70 to 80 percent of the metabolic disposition) exert downstream effects on multiple neurotransmitter systems: enhancement of acetylcholine release in the prefrontal cortex and hippocampus via group II metabotropic glutamate receptor modulation; site-specific activation of dopaminergic and serotonergic transmission in the mesocorticolimbic pathway through nicotinic acetylcholine receptor mechanisms; and anxiolytic activity mediated through an interaction between cholinergic, dopaminergic, and serotonergic systems [3, 4, 5]. The pharmacokinetic profile of aniracetam is characterized by rapid and complete gastrointestinal absorption, extremely low systemic bioavailability of the parent compound (approximately 0.2 percent) due to extensive first-pass hepatic hydrolysis, and a plasma elimination half-life of approximately 35 minutes [6, 7]. The parent compound is rapidly cleaved to yield three primary metabolites: N-anisoyl-GABA (70 to 80 percent), 2-pyrrolidinone (20 to 30 percent), and p-anisic acid (20 to 30 percent), each of which has been shown to contribute to the pharmacological activity profile [8]. The clinical evidence base for aniracetam derives principally from two double-blind, placebo-controlled multicenter trials in elderly patients with mild to moderate senile dementia of the Alzheimer type (SDAT), in which aniracetam at 1500 mg per day for six months produced statistically significant improvement in cognitive and psychobehavioral parameters relative to placebo and, in one trial, relative to piracetam at 2400 mg per day [9, 10]. A comparative open-label study in 276 patients with cognitive disorders demonstrated preservation of neuropsychological parameters for at least 12 months with aniracetam monotherapy and performance comparable to or exceeding cholinesterase inhibitor monotherapy in mildly demented patients [11]. Preclinical pharmacology is extensive and demonstrates cognitive enhancement in scopolamine-induced amnesia, cerebral ischemia, and age-related cognitive decline models; anxiolytic activity in elevated plus-maze, conditioned fear, and social interaction paradigms; neuroprotection against excitotoxicity and ischemic injury; and activation of brain-derived neurotrophic factor synthesis [12, 13, 14]. The compound was marketed as a prescription medicine in Japan (Draganon, subsequently withdrawn), in Italy (Ampamet), and in Greece (Memodrin, Referan) for cognitive impairment associated with cerebrovascular disease and neurodegenerative conditions. It is not approved by the United States Food and Drug Administration and is not a controlled substance in the United States, where it is sold as a research compound. This monograph reviews the chemistry, synthesis, and structural pharmacology of aniracetam; the multi-target mechanism of action spanning AMPA receptor modulation, metabotropic glutamate receptor effects, and monoaminergic neuromodulation; the comprehensive pharmacokinetic record including active metabolite characterization; the preclinical pharmacology across cognitive, anxiolytic, and neuroprotective domains; the clinical evidence base in dementia and cognitive impairment; sourcing and quality verification; reconstitution and handling; stack-interaction considerations; adverse events and safety; and a comparative assessment of five racetam and ampakine alternatives against aniracetam on five competency standards.

    Read the full monograph

    The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

    KDC-MN-1426Open in new tab →

    Download PDF →

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.